Gabapentin and Weed: What the Sedation Risk Is

Almost every drug interaction question in this series turns out to be a liver enzyme question. Gabapentin is the exception, and that makes it unusually clean to answer: gabapentin is not appreciably metabolized at all. It leaves the body through the kidneys largely unchanged, so the enzyme inhibition that dominates cannabis interaction research has nothing to act on.

That removes the pharmacokinetic question almost entirely. What it leaves is a pharmacodynamic one, and unlike most of the speculation in this field, it is backed by an FDA safety communication.

Can You Take Gabapentin and Weed Together?

The honest answer has two halves that point in different directions.

There is no known mechanism by which cannabis would change gabapentin blood levels, and no known mechanism by which gabapentin would change cannabinoid levels. On the metabolic side this is close to a non-question.

On the effects side it is a real question. Both substances depress the central nervous system, the effects are additive, and the FDA has warned about gabapentin combined with other CNS depressants specifically in the context of breathing problems. That warning does not name cannabis, and no study has measured the combination. The mechanism it describes is not exotic, though, and cannabis is a CNS depressant by the same functional definition.

Why Gabapentin Skips the Liver Enzyme Problem

Gabapentin's prescribing information states that it is not appreciably metabolized, that it does not interfere with the metabolism of commonly coadministered antiepileptic drugs, that it is substantially excreted by the kidney, and that it can be removed by hemodialysis.

Every one of those facts points the same way. A drug that is not metabolized cannot have its metabolism inhibited. The CYP3A4 story that drives the antibiotics question and the CYP2C9 story that drives the ibuprofen question simply do not apply here.

One practical consequence follows from the renal route rather than the cannabis question: because gabapentin clearance depends on kidney function, reduced kidney function raises gabapentin exposure. That is a dose conversation with the prescriber, and it is independent of anything on this page.

What Is the Real Risk Then?

Additive central nervous system depression.

Gabapentin causes somnolence, dizziness and impaired coordination in a meaningful fraction of patients. Cannabis, particularly at higher THC doses and particularly taken orally, causes sedation and impairs coordination and judgment. Taken together the reasonable expectation is more of both than either produces alone.

This is not a dramatic or exotic risk. It is the ordinary kind, and the ordinary kind is what actually causes harm: a fall, a car crash, a misjudged dose of something else. The people carrying the most of it are older adults, anyone with reduced lung function, and anyone whose medication list already includes opioids or other sedatives.

The FDA Breathing Warning

In December 2019 the FDA issued a drug safety communication about serious breathing difficulties in patients taking gabapentin or pregabalin who have respiratory risk factors. The risk factors it identifies include the use of opioid pain medicines and other drugs that depress the central nervous system, and respiratory conditions such as COPD. The FDA required new warnings about respiratory depression to be added to the prescribing information for the gabapentinoids.

Separately, fatal respiratory depression has been reported with gabapentin overdose, both alone and in combination with other CNS depressants.

Two things have to be said precisely here.

What the warning does say: other CNS depressants, as a category, raise the risk of serious breathing problems on gabapentin, and that risk is concentrated in people who already have respiratory vulnerability.

What it does not say: it does not name cannabis, and no study has measured cannabis with gabapentin for this or any other endpoint. Reading cannabis into the category is an inference. It is a reasonable one, because cannabis produces CNS depressant effects and the warning is written around a mechanism rather than a specific drug list, but it remains an inference and this article is not going to dress it up as more.

The practical takeaway does not depend on resolving that. If you have COPD, sleep apnea, another respiratory condition, or you take opioids alongside gabapentin, the combination deserves a conversation before it happens rather than after.

What About Cannabis as an Alternative to Gabapentin?

Out of scope here, deliberately.

Gabapentin is prescribed for seizures, for postherpetic neuralgia and commonly off label for various nerve pain conditions. Whether cannabis is useful for any of those is a different question with a different evidence base, and this article makes no claim about it.

The safety point is simple and worth stating plainly: stopping an antiseizure medication without medical supervision carries real risk independent of anything to do with cannabis. Any change to a gabapentin regimen belongs to the prescriber.

What Should You Tell Your Physician?

Say that you use cannabis, roughly how much, and by what route, because oral cannabis is more sedating and longer lasting than inhaled and that difference matters for this specific interaction.

Also say whether you take anything else sedating, opioids in particular, and whether you have any respiratory condition. Those two answers are what actually move this from a low priority mention to something worth planning around.

What This Means for Florida, Georgia, and Texas Patients

Gabapentin on a medication list is not a barrier to certification in any of the three programs. Miracle Leaf® physicians review the full list as part of the evaluation, and a sedating medication is exactly the kind of entry that changes the conversation about route and dose rather than about eligibility.

Chronic pain qualifies in all three states, and the chronic pain page covers that. The Florida marijuana laws, Georgia marijuana laws, and Texas marijuana laws pages cover each program, and the Florida, Georgia, and Texas pages cover how certification works.

What If You Live Outside Florida, Georgia, and Texas?

Miracle Leaf® operates clinics in Florida, Georgia, and Texas and offers telehealth evaluations in additional states. The telehealth page covers which states are served. The states where cannabis is legal post covers the national picture.

Sources for Cannabis and Gabapentin

• Neurontin, Gralise, Horizant (gabapentin) and Lyrica, Lyrica CR (pregabalin): Drug Safety Communication, Serious Breathing Problems. US Food and Drug Administration, December 2019. Source of the respiratory risk factors named, the inclusion of opioids and other CNS depressants and COPD, and the requirement to add respiratory depression warnings to the prescribing information.
• GABAPENTIN tablet, film coated. FDA structured product label, DailyMed. Source of the statements that gabapentin is not appreciably metabolized, does not interfere with the metabolism of commonly coadministered antiepileptic drugs, is substantially excreted by the kidney, and is removed by hemodialysis, and of the reported respiratory depression with concomitant CNS depressants.
• Respiratory concerns of gabapentin and pregabalin. Source of context on the gabapentinoid respiratory signal and its pharmacovigilance history.

Related Health and Eligibility Resources

• The cannabis and Xanax post covers benzodiazepines, the other additive sedation question in this series.
• The cannabis and alcohol post covers the most common CNS depressant combination of all.
• The cannabis and ibuprofen post covers the pain medication most often taken alongside gabapentin.
• The chronic pain page covers eligibility in all three programs.

Talk to a Physician About Your Medication List

Bring the gabapentin dose, anything else sedating on the list, and whether you have a respiratory condition. Those three answers shape the recommendation.

Call (833) LEGAL-MJ or contact us online to book. Evaluation pricing is on the pricing page, and the clinicians who review this content are listed on the editorial team page.

Disclaimer

This post is informational and is not medical advice. No published study has measured cannabis with gabapentin for any endpoint. The FDA safety communication cited here names opioids and other CNS depressants as a category and does not name cannabis; treating cannabis as belonging to that category is a mechanistic inference stated as such and not a finding. This article does not evaluate whether cannabis treats any condition gabapentin is prescribed for. Do not stop, reduce or otherwise change a gabapentin regimen based on this article. Abruptly stopping an antiseizure medication can be dangerous. Discuss cannabis use with the physician who prescribes your gabapentin.